Enhanced intracellular drug delivery of pH-sensitive doxorubicin/poly(ethylene glycol)-block-poly(4-vinylbenzylphosphonate) nanoparticles in multi-drug resistant human epidermoid KB carcinoma cells
Source abstract
Abstract
A pH-sensitive nanoparticle was prepared using our original amphiphilic block copolymer, poly(ethylene glycol)-b-poly(4-vinylbenzylphosphonate) (PEG-b-PVBP), which possesses phosphate groups as a side chain of its hydrophobic segment (termed here, phosphate nanoparticle (PNP)). The cationic anticancer drug, doxorubicin (DOX) was incorporated into a PNP (DOX@PNP), and its loading capacity was 320 mg g−1-PNP. Electrostatic and hydrophobic interactions in the core of the PNP might act synergistically to significantly improve its loading capacity. The cytotoxicity of the DOX@PNP was examined using the drug-sensitive human epidermoid KB carcinoma cell line (KB-3-1) and two different multi-drug resistance (MDR) KB cell lines (P-glycoprotein (P-gp) overexpressed (KB-C-2) and multidrug resistance protein 1 (MRP1) overexpressed (KB/MRP) cell lines). The DOX@PNP displayed a lower cytotoxic activity than free DOX against KB-3-1 cells. In contrast, the DOX@PNP showed a higher cytotoxic activity than free DOX against MDR cells. Of particular note, the cytotoxicity of the DOX@PNP against KB-C-2 cells was much higher than that against KB/MRP cells, suggesting that different mechanisms of drug reflux via the ATP binding cassette (ABC) transporting system play an important role in nanoparticle-assisted chemotherapy. Observation with confocal laser scanning microscopy (CLSM) indicated that the DOX@PNP was taken up by cells via the endocytosis pathway. The DOX@PNP was initially localized in the late endosome and lysosome, with the subsequent release of DOX from the DOX@PNP in response to the acidic pH of the late endosome and lysosome. Quantitative analysis using flow cytometry confirmed that the uptake of the DOX@PNP into KB-C-2 cells was much higher than that into KB/MRP cells, which was one of the reasons for the enhanced toxicity of the DOX@PNP against KB-C-2 cells compared to that against KB/MRP cells. Reflux of the liberated free DOX in the cytosol, via an endosomal membrane transporter, is considered one of the reasons for the low efficiency of DOX@PNP chemotherapy against KB/MRP cells. However, compared to the free DOX dose, a high dose of the DOX@PNP was effectively delivered to the nuclei of the KB/MRP cells. On the basis of these results, the pH-sensitive DOX@PNP is anticipated as one of the effective chemotherapeutic drugs with enhanced cytotoxicity for multiple types of MDR cancer cells.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · Drug Transport and Resistance Mechanisms · RNA Interference and Gene Delivery
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (32)
Show source-provided references
1. Gottesman · Nat. Rev. Cancer · 2002 · 2 · 4810.1038/nrc706 ↗
2. Szakács · Nat. Rev. Drug Discovery · 2006 · 5 · 21910.1038/nrd1984 ↗
3. Gottesman · J. Biol. Chem. · 1988 · 263 · 1216310.1016/S0021-9258(18)37730-5 ↗
4. Endicott · Annu. Rev. Biochem. · 1989 · 58 · 13710.1146/annurev.bi.58.070189.001033 ↗
5. Ambudkar · Oncogene · 2003 · 22 · 746810.1038/sj.onc.1206948 ↗
6. Cole · Science · 1992 · 258 · 165010.1126/science.1360704 ↗
7. Hipfner · Biochim. Biophys. Acta · 1999 · 1461 · 35910.1016/S0005-2736(99)00168-6 ↗
8. Borst · J. Natl. Cancer Inst. · 2000 · 92 · 129510.1093/jnci/92.16.1295 ↗
9. Doyle · Proc. Natl. Acad. Sci. U. S. A. · 1998 · 95 · 1566510.1073/pnas.95.26.15665 ↗
10. Gottesman · Annu. Rev. Biochim. · 1993 · 62 · 38510.1146/annurev.bi.62.070193.002125 ↗
11. Oh · Int. J. Mol. Sci. · 2009 · 10 · 377610.3390/ijms10093776 ↗
12. Akiyama · Somat. Cell. Mol. Genet. · 1985 · 11 · 11710.1007/BF01534700 ↗
13. Taguchi · FEBS Lett. · 1997 · 401 · 1110.1016/S0014-5793(96)01421-4 ↗
14. Kataoka · Adv. Drug Delivery Rev. · 2001 · 47 · 11310.1016/S0169-409X(00)00124-1 ↗
15. Kabanov · J. Controlled Release · 2002 · 82 · 18910.1016/S0168-3659(02)00009-3 ↗
16. Rapoport · Prog. Polym. Sci. · 2007 · 32 · 96210.1016/j.progpolymsci.2007.05.009 ↗
17. Bae · Adv. Drug Delivery Rev. · 2009 · 61 · 76810.1016/j.addr.2009.04.016 ↗
18. Matsumura · Cancer Res. · 1986 · 46 · 6387
19. Oishi · J. Mater. Chem. · 2007 · 17 · 372010.1039/b706973a ↗
20. Oishi · React. Funct. Polym. · 2007 · 67 · 131110.1016/j.reactfunctpolym.2007.07.009 ↗
21. Jabr-Milane · Cancer Treat. Rev. · 2008 · 34 · 59210.1016/j.ctrv.2008.04.003 ↗
22. Lee · J. Controlled Release · 2008 · 129 · 22810.1016/j.jconrel.2008.04.024 ↗
23. Lee · J. Controlled Release · 2008 · 132 · 16410.1016/j.jconrel.2008.05.003 ↗
24. Saad · Nanomedicine (Lond) · 2008 · 3 · 76110.2217/17435889.3.6.761 ↗
25. Danquah · Adv. Drug Delivery Rev. · 2011 · 63 · 62310.1016/j.addr.2010.11.005 ↗
26. Prasad · Drug Delivery Transl. Res. · 2012 · 2 · 9510.1007/s13346-011-0051-1 ↗
27. Murakami · Sci. Transl. Med. · 2011 · 3 · 64ra210.1126/scitranslmed.3001385 ↗
28. Cabral · Nat. Nanotechnol. · 2011 · 6 · 81510.1038/nnano.2011.166 ↗
29. Kamimura · J. Controlled Release · 2012 · 160 · 48610.1016/j.jconrel.2012.04.027 ↗
30. Kamimura · Nanoscale · 2011 · 3 · 370510.1039/c1nr10466g ↗
31. Meng · ACS Nano · 2010 · 4 · 453910.1021/nn100690m ↗
32. Okumura · Mol. Pharmacol. · 2000 · 58 · 156310.1124/mol.58.6.1563 ↗